Loading...
XNAS
ACRV
Market cap42mUSD
Jun 06, Last price  
1.35USD
1D
8.00%
1Q
-75.63%
IPO
-91.94%
Name

Acrivon Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-81m
L+33.40%
-5,306,000-16,243,000-29,677,000-60,388,000-80,556,000
CFO
-66m
L+54.00%
-2,803,000-13,982,000-30,117,000-42,641,000-65,669,000

Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
IPO date
Nov 15, 2022
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
89,199
67,237
33,752
Unusual Expense (Income)
NOPBT
(89,199)
(67,237)
(33,752)
NOPBT Margin
Operating Taxes
(1,490)
Tax Rate
NOPAT
(89,199)
(67,237)
(32,262)
Net income
(80,556)
33.40%
(60,388)
103.48%
(29,677)
82.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
69,997
(257)
104,458
BB yield
-3.44%
0.24%
-41.37%
Debt
Debt current
1,057
1,754
726
Long-term debt
6,233
8,411
9,196
Deferred revenue
Other long-term liabilities
Net debt
(177,279)
(117,707)
(159,710)
Cash flow
Cash from operating activities
(65,669)
(42,641)
(30,117)
CAPEX
(2,768)
(1,288)
(2,166)
Cash from investing activities
(51,771)
50,717
(141,676)
Cash from financing activities
121,027
(1,554)
101,709
FCF
(89,316)
(68,283)
(33,333)
Balance
Cash
179,480
127,458
127,751
Long term investments
5,089
414
41,881
Excess cash
184,569
127,872
169,632
Stockholders' equity
(196,498)
(116,480)
125,121
Invested Capital
376,929
243,196
50,315
ROIC
ROCE
EV
Common stock shares outstanding
337,918
22,078
21,921
Price
6.02
22.36%
4.92
-57.29%
11.52
 
Market cap
2,034,267
1,772.75%
108,625
-56.98%
252,526
 
EV
1,856,988
(9,082)
274,042
EBITDA
(88,193)
(66,701)
(33,388)
EV/EBITDA
0.14
Interest
1,490
Interest/NOPBT